Pediatric Praziquantel Consortium
World NTD Day 2021 and the launch of the new WHO NTD road map
On 30 January 2021, communities around the world will rally together to observe the second annual World Neglected...
Pediatric Praziquantel Consortium to participate in ISNTD Connect GSA webinar
The Pediatric Praziquantel Consortium has been invited to participate in a webinar jointly hosted by the...
A new formulation to fight Schistosomiasis
A pediatric formulation of Praziquantel has been developed for schistosomiasis.
Video credits: The GHIT Fund
Vision
Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.
Mission
Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.
Development program
The consortium established a pediatric drug development program, divided into three major steps: preclinical development, clinical development and registration and access.
The pediatric formulation
A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.
